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ORIGINAL ARTICLE
The use of bare metal stents (BMS) in percuta-
neous coronary intervention (PCI) has decreased
the restenosis rate to 15–30% compared with bal-
loon angioplasty only.1 Recent randomized clinical
trials and large post-marketing registries on new
drug eluting stents (DES) show further reduction
of restenosis and major adverse cardiac event
(MACE) to <10–15%.2–4 Furthermore, with the use
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Background/Purpose: Drug eluting stents (DES) have been shown to reduce in-stent restenosis rate and target
vessel revascularization in large clinical trials. However, the safety and efficacy of DES use in the Taiwanese
population has not been reported. We designed this trial to analyze the clinical results in patients using
DES in a single tertiary center.
Methods: We retrospectively analyzed the clinical data of all patients treated at National Taiwan
University Hospital, Taipei, Taiwan, with sirolimus- or paclitaxel-eluting stents between September 2003
and January 2005.
Results: A total of 585 patients (466 men, 119 women; mean age, 64.5 ±11.2 years) were enrolled. Meanwhile,
205 sirolimus- and 717 paclitaxel-eluting stents were implanted, with a mean of 1.6 stents per patient.
Half (50.2%) of the stents were placed in the left anterior descending artery. Among the enrolled patients,
41.8% had diabetes mellitus, 25% had a diagnosis of acute coronary syndrome, and 10.7% was treated
with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Overall
8-month target vessel revascularization, major adverse cardiac event rate, and cardiac death rate were 8.8%,
9.7% and 2.5%, respectively. There was no difference in clinical events between sirolimus- and paclitaxel-
eluting stents. The overall subacute stent thrombosis rate was 1.36%, significantly lower than that in patients
who presented with acute coronary syndrome (4%).
Conclusion: The use of DES in the Taiwanese population yielded comparable results as those in large clinical
trials. Subacute stent thrombosis rate was higher in acute coronary syndrome. The safety of DES in these
situations should be further clarified. [J Formos Med Assoc 2007;106(8):624–630]
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of DES, long-term outcome became comparable
to that of coronary artery bypass graft (CABG)
surgery, as shown in the recent ARTS II trial.5
Many lesions that were previously thought to be
associated with high restenosis rates or were rela-
tive contraindications to angioplasty, such as un-
protected left main disease (UPLM), multivessel
disease (MVD), chronic total occlusion (CTO),
bifurcation lesion and saphenous vein graft (SVG),
have become everyday practice after the introduc-
tion of DES. Furthermore, the success of DES in
elective conditions has led to its use in acute coro-
nary syndrome (ACS) and ST-segment elevation
myocardial infarction (STEMI). The use of DES in
Taiwan, which was initiated in 2003, remains lim-
ited by its high cost. Therefore, we aimed to report
the first series of DES use in a tertiary medical
center in Taiwan.
Materials and Methods
This retrospective observational study enrolled
all patients treated between September 2003 
and January 2005 with sirolimus-eluting stents
(CYPHER®; Cordis Corp., A Johnson & Johnson
Company, Miami, FL, USA) and paclitaxel-eluting
stents (TAXUS®; Boston Scientific Corp., Natick,
MA, USA) at National Taiwan University Hospital.
Intravenous heparin was administered at a
dose of 70–100 U/kg to keep activated clotting
time > 250 seconds. Aspirin 100 mg once daily
was given to those patients without contraindica-
tions and was continued indefinitely. Clopidogrel
300 mg was loaded just before stenting and then
maintained at 75 mg/day for 3 months according
to our current health insurance guideline. The use
of glycoprotein IIb/IIIa inhibitor depended on
the decision of operators. The choice between
sirolimus-eluting stent (SES) and paclitaxel-eluting
stent (PES) was decided by the patient and family
according to individual economic considerations.
PCI was performed according to lesion charac-
teristics; predilation or direct stenting was deter-
mined by the operator. Stent length was carefully
judged in order to cover the full length of the lesion
without any gap between stents if more than two
stents were placed.
Stent thrombosis was diagnosed as ACS with
angiographic documentation of either occlusion of
the target lesion or thrombus within the previously
stented segment.
Myocardial infarction after intervention was
defined as either the development of pathologic
Q waves lasting at least 0.4 seconds in at least two
contiguous leads with an elevated creatine kinase
MB fraction level or, in the absence of pathologic
Q waves, an elevation in creatine kinase levels to
more than twice the upper limit of normal with
an elevated creatine kinase MB level. Major adverse
cardiac events were defined as death, myocardial
infarction, or target vessel revascularization (TVR)
with either PCI or CABG. Death was attributed to
cardiac death unless proven otherwise.
Statistical analysis
Continuous variables were presented as mean ±
standard deviation and compared by Student’s 
t test. Categorical variables were presented as
counts and percentages and compared by Fisher’s
exact test. All statistical tests were two-tailed.
Kaplan–Meier curves were plotted to represent the
cumulative incidence of adverse events. Forward
stepwise multivariate logistic regression analysis
was performed to identify variables independently
associated with stent thrombosis.
Results
Between September 2003 and January 2005, 585
patients (466 men, 119 women) with a mean age of
64.5 ± 11.2 years were enrolled. Baseline character-
istics are presented in Table 1. A total of 922 DESs
were implanted with a mean of 1.6 stents per pa-
tient. Half (50.2%) of the stents were placed in
the left anterior descending artery (Table 2). One
hundred and twenty patients (20.5%) received
205 SES implantations and 465 patients (79.5%)
received 717 PES. Among the patients, 41.8% had
diabetes mellitus, 25% had a diagnosis of ACS, and
10.7% was treated with primary PCI for STEMI.
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Clinical follow-up was completed in 561 
patients (95.9% of the total population). Overall
8-month TVR rate, major adverse cardiac event
rate, and cardiac death rate were 8.8%, 9.7% and
2.5%, respectively. TVR, non-fatal MI, cardiac
death, and total MACE at 8 months were not sta-
tistically different in the SES and PES groups
(Table 3). The Kaplan–Meier curves are shown in
Figures 1–3.
Twenty-seven patients underwent unpro-
tected left main (LM) stem stenting (4.6%) and
67% of these patients had bifurcation lesion of
the distal LM. Left ventricular ejection fraction
(LVEF) was 59.2 ± 11.6%. The clinical outcomes
of these 27 patients were: TVR, 27.7% (25% for
SES group, 11% for PES group, p = 0.563); cardiac
death, 11.1% (25% for SES group, 5.6% for PES
group, p = 0.215); MACE, 22.2% (37.5% for SES
group, 16.6% for PES group, p = 0.33). Comparing
clinical outcomes at 8 months between the LM
stenting and the non-LM stenting groups, there
was a significant difference in cardiac death (11.1%
for LM stenting group vs. 2.1% for non-LM stent-
ing group, p = 0.028) and a trend toward higher
Table 1. Baseline characteristics*
SES PES p
Patient number (stent number) 120 (205) 465 (717)
Age (yr) 64.3 ± 11.2 64.5 ± 11.2 0.835
Male 97 (80.8) 369 (79.4) 0.898
Diabetes mellitus 45 (37.5) 199 (42.8) 0.349
Hypertension 85 (70.8) 315 (67.7) 0.508
Hyperlipidemia 52 (43.3) 196 (42.2) 0.835
Smoking 21 (17.5) 80 (17.2) 1.000
Prior MI 14 (11.7) 78 (16.8) 0.205
Prior CABG 10 (8.3) 25 (5.4) 0.278
ACS 25 (20.8) 124 (26.7) 0.239
STEMI 9 (7.5) 54 (11.6) 0.247
*Data are presented as mean± standard deviation or n (%). SES = sirolimus-eluting stent; PES = paclitaxel-eluting stent; MI = myocardial
infarction; CABG = coronary artery bypass graft; ACS = acute coronary syndrome; STEMI = ST-segment elevation myocardial infarction.
Table 2. Location of lesions and number of diseased vessels*
SES PES p
Location of lesion 0.201
LM 8 19
LAD 107 356
LCx 40 166
RCA 48 182
RI 3 2
SVG 4 2
LIMA 0 2
Number of diseased vessels 0.162
1 29 (24.2) 97 (20.9)
2 32 (26.7) 147 (31.6)
3 58 (48.3) 216 (46.5)
*Data are presented as n or n (%). SES = sirolimus-eluting stent; PES = paclitaxel-eluting stent; LM = left main; LAD = left anterior 
descending; LCx = left circumflex; RCA = right coronary artery; RI = ramus intermedius; SVG = saphenous vein graft; LIMA = left internal
mammary artery.
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all-cause mortality in the LM stenting group (11.1%
for LM stenting group vs. 3.5% for non-LM stent-
ing group, p = 0.084). There were no differences in
8-month TVR and MACE between the two groups
(TVR rate: 14.8% for LM stenting group vs. 8.6%
for non-LM stenting group, p = 0.29; MACE rate:
14.8% for LM stenting group vs. 9.5% for non-LM
stenting group, p = 0.323).
Of the 585 patients, 22.4% had one-vessel dis-
ease, 30.8% had two-vessel disease, and 46.5% had
three-vessel disease. Comparing 8-month clinical
event rate in patients with one-vessel disease and
those with multivessel disease, there were signifi-
cant lower TVR rate (3.0% vs. 11.0%, p=0.003) and
MACE rate (3.0% vs. 11.2%, p = 0.02). However,
Table 3. Eight-month clinical outcome*
SES PES p
MACE 8 (6.6) 49 (10.5) 0.23
TVR 7 (5.8) 45 (9.6) 0.277
Nonfatal MI 2 (1.6) 8 (1.7) 1.00
Cardiac death 2 (1.6) 13 (2.7) 0.747
All-cause mortality 3 (2.5) 20 (4.3) 0.597
*Data are presented as n (%). SES = sirolimus-eluting stent; PES = paclitaxel-eluting stent; MACE = major cardiovascular event; TVR = target
vessel revascularization; MI = myocardial infarction.
Figure 1. Kaplan–Meier estimated survival free from car-
diac death of patients who received sirolimus-eluting stent
(SES) or paclitaxel-eluting stent (PES).
Figure 2. Kaplan–Meier estimated survival free from death,
re-infarction, or target vessel revascularization of patients
who received sirolimus-eluting stent (SES) or paclitaxel-
eluting stent (PES).
Figure 3. Kaplan–Meier estimated survival free from target
vessel revascularization of patients who received sirolimus-
eluting stent (SES) or paclitaxel-eluting stent (PES).
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there was no difference in 8-month cardiac death
and all-cause mortality between the two groups
(Table 3).
Eight patients (1.37%) developed stent throm-
bosis after DES implantation. The case fatality
rate with stent thrombosis was 87.5% (7 of the 
8 patients with stent thrombosis died). DES im-
plantation during ACS was associated with a higher
risk for stent thrombosis (6 events in 149 ACS vs.
2 events in 436 non-ACS; 4% vs. 0.4%, p = 0.005)
(Table 4).
Discussion
This study presented the first series of DES use in
Taiwan. The main findings of this study were that
overall 8-month TVR, MACE, and cardiac death
rates were 8.8%, 9.7% and 2.5%, respectively. Stent
thrombosis rate was 1.37%, higher in urgent PCI.
There was no significant difference in clinical
events at 8 months between the two DES groups.
LM PCI with DES was associated with higher 
8-month cardiac death and a trend toward higher
8-month all-cause mortality. The results were com-
patible with previous randomized control trials in
which the MACE rate at 9 months was 4.0–9.3%
for SES and 8.5–16.4% for PES.2,5–10
There was a high prevalence of diabetes mellitus
(41.8%) in these patients. Diabetes mellitus was
associated with a higher incidence of myocardial
infarction at 8 months and a trend toward more
total MACE, but not with other clinical events.
There did not appear to have any significant dif-
ference in the clinical events between SES and PES.
In the balloon angioplasty era, the restenosis rate
after angioplasty in diabetes mellitus patients
reached 62%. After the introduction of coronary
stents, the restenosis rate decreased to 27%.11,12
Exaggerated intimal hyperplasia has been shown to
be the major factor for the higher restenosis rate.13
In the SIRIUS trials, DES was shown to have a
significant reduction of MACE and TVR in the 
diabetic group, compared with BMS (9 months,
MACE 9.2% vs. 25%, TVR 6.9% vs. 22.3%).14
Compared with these studies in which BMS were
applied, both DES were effective in reducing TVR
and clinical event compared with BMS in the
Taiwanese population.
We also demonstrated that the 8-month MACE
rate was significantly higher in the multivessel
group. There was no difference in cardiac death and
all-cause mortality. In the BMS era, various trials
have shown that survival was similar between stent-
ing and CABG. In the Arterial Revascularization
Therapy Study (ARTS I), 1205 patients with mul-
tivessel disease were randomized to either PCI or
CABG. There was no significant difference in mor-
tality, but more TVR and MACE occurred in the
BMS group.15 Our study demonstrated the benefit
of using DES over BMS in multivessel PCI. In ad-
dition, several large trials comparing the effect of
DES and CABG in multivessel disease (e.g. ARTS II,
SYNTAX, FREEDOM) are now ongoing, aiming to
identify the best revascularization strategy in this
high-risk group.
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Table 4. Subacute thrombosis (SAT) rate
SAT rate (%) p
ACS vs. non-ACS 4 0.4 0.005
SES vs. PES 0.8 1.5 1.00
LM stenting vs. non-LM stenting 3.7 1.1 0.292
DM vs. non-DM 2.05 0.88 0.289
HTN vs. non-HTN 0.75 2.74 0.116
Smoking vs. non-smoking 0.99 1.46 1.00
Prior MI vs. no history of MI 2.17 1.23 0.619
Prior CABG vs. no history of CABG 2.85 1.28 0.394
ACS = acute coronary syndrome; SES = sirolimus-eluting stent; PES = paclitaxel-eluting stent; LM = left main; DM = diabetes mellitus;
HTN = hypertension; MI = myocardial infarction; CABG = coronary artery bypass graft.
LM stenting was associated with a significantly
higher 8-month cardiac death and a trend toward
higher 8-month all-cause mortality compared with
non-LM patients. CABG was once thought to be
the treatment of choice in UPLM disease. After
the introduction of DES, there has been renewed 
interest regarding percutaneous treatment of LM
disease. Park et al16 demonstrated that 1-year event-
free survival was 98% in the DES group and 81%
in the BMS group in their LM PCI series (with 70%
at distal bifurcation). In another report from Milan
(with 88% at the distal bifurcation), MACE at 
6 months (24.7% vs. 42.1%) and TVR rate (18.8%
vs. 30.6%) were lower in the DES group.17 Our
sample size was too small to draw a definite con-
clusion for LM PCI. In addition, although DES
for LM lesion decreased the restenosis rate com-
pared with BMS, there was still 22% MACE and
27% TVR.
Subacute stent thrombosis developed in eight
patients (1.36%) but no late stent thrombosis was
observed in our study. Excess stent thrombosis
had been suspected during the early period after
the marketing of DES in 2003/2004. Many large
randomized trials have shown that the overall
stent thrombosis rate in DES is not higher than
that of BMS. In a series of 2229 patients under-
going SES and PES implantation at two centers,
the mean stent thrombosis rate at an average time
of 9.3 months was 1.3%. However, stent throm-
bosis rate was significantly increased in several
high-risk subsets, including thrombotic lesions,
diabetes mellitus, bifurcation lesion treated with
two stents, unprotected LM disease, and patients
with renal failure and/or left ventricular dysfunc-
tion.18 In our study, overall stent thrombosis rate
with DES use was comparable to the report by
Lakovou et al, and was not different from that in
the BMS era (around 1.6%).18,19 We also found that
ACS was associated with a higher stent thrombosis
rate. In a study of BMS, most cases of stent throm-
bosis occurred in high-risk circumstances, includ-
ing ACS, multistent interventions, and treatment
of 3.0-mm or smaller vessels. Mortality following
stent thrombosis was particularly high (48%) in
their registry.20
This study is the first clinical experience of DES
use in Taiwan. We have shown a consistent benefit
of DES across different clinical conditions. How-
ever, the use of DES in ACS requires great caution.
Further clinical trials and clinical experience are
needed to demonstrate the safety of DES.
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